UK Markets closed

Navidea Biopharmaceuticals, Inc (NAVB)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
1.1500-0.0700 (-5.74%)
At close: 04:00PM EST
1.2000 +0.05 (+4.35%)
After hours: 05:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2200
Open1.1900
Bid1.1500 x 1300
Ask1.1800 x 1000
Day's range1.1202 - 1.2325
52-week range1.1200 - 3.1500
Volume46,742
Avg. volume59,725
Market cap33.379M
Beta (5Y monthly)1.66
PE ratio (TTM)N/A
EPS (TTM)-0.4520
Earnings date11 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.50
  • Zacks

    Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should Know

    Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

    DUBLIN, Ohio, November 03, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, November 10, 2021 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2021.

  • Business Wire

    Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

    DUBLIN, Ohio, October 26, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of